<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Agent Cancer</journal-id><journal-title>Infectious Agents and Cancer</journal-title><issn pub-type="epub">1750-9378</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19149879</article-id><article-id pub-id-type="pmc">2640373</article-id><article-id pub-id-type="publisher-id">1750-9378-4-2</article-id><article-id pub-id-type="doi">10.1186/1750-9378-4-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Antiviral therapy in acute viral hepatitis B: why and when</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Morelli</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>pinomorelli25@libero.it</email></contrib><contrib id="A2" corresp="yes" contrib-type="author"><name><surname>Perrella</surname><given-names>Alessandro</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>alexperrel@virgilio.it</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Sbreglia</surname><given-names>Costanza</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>drcosty@libero.it</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Bellopede</surname><given-names>Pasquale</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>pbellop@libero.it</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Riccio</surname><given-names>Vincenzo</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>oreste.perrella@ospedalecotugno.it</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Perrella</surname><given-names>Oreste</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>oreste.perrella@ospedalecotugno.it</email></contrib></contrib-group><aff id="I1"><label>1</label>VII Department of Infectious Diseases and Immunology, "D. Cotugno" Hospital, Naples, Italy</aff><aff id="I2"><label>2</label>"Liver Unit," A. Cardarelli Hospital, Naples, Italy</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>16</day><month>1</month><year>2009</year></pub-date><volume>4</volume><fpage>2</fpage><lpage>2</lpage><ext-link ext-link-type="uri" xlink:href="http://www.infectagentscancer.com/content/4/1/2"/><history><date date-type="received"><day>30</day><month>7</month><year>2008</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Morelli et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Morelli et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>               Morelli               Giuseppe                              pinomorelli25@libero.it            </dc:author><dc:title>            Antiviral therapy in acute viral hepatitis B: why and when         </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Infectious Agents and Cancer 4(1): 2-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1750-9378(2009)4:1&#x0003c;2&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1750-9378</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>Acute viral hepatitis B is cleared in more than 95% of patients, while the remainder ones may develop either chronic HBV infection or, rarely, fulminant hepatitis.</p><p>Therefore there are elderly patients with severe acute HBV hepatitis caractherized by high serum bilirubin levels &#x0003e;15 mmole/dl, international normalized ratio (INR) with value more than 1.6; these patients are caractherized by a severe outcome of HBV infection.</p><p>As known, outcome of infection and the pathogenesis of liver diseases are determined by viral and host factors, such as T reg lymphocytes.</p><p>T regs may be associated with a negative immune response such as an inhibition of gamma- IFN secretion.</p><p>The impact of viral load on antiviral T cell responses may play a critical role in thaese patients, influencing disease persistence and immune response.</p><p>Antiviral drugs could be useful in these patients determing a possible down -regulation of T regs.</p></abstract></article-meta></front><body><sec><title>Letter to the editor</title><p>Dear Editor,</p><p>Acute viral hepatitis B is cleared in more than 95% of patients, while the remainder ones may develop either chronic HBV infection or, rarely, fulminant hepatitis. [<xref ref-type="bibr" rid="B1">1</xref>] The role of antivirals, such as lamivudine or entecavir, in acute HBV infection, has not been evaluated in controlled trials.</p><p>Lamivudine administration shows an antiviral efficacy in patients with HbeAg positive and HbeAg negative.</p><p>Among the patients with acute infection there are elderly subjects with severe course and severe outcome of HBV hepatitis.</p><p>A logical hypothesis for these patients is that a rapid decrease in the HBVDNA levels trough the use of antiviral agents could result in a less intense host response against HBV virus.</p><p>Today, increased knowledge of the virological and immunological events to HBV infection permits to define the mechanisms involved in viral clearance, persistence and disease severity.</p><p>Outcome of infection and the pathogenesis of liver disease are determined by viral and host factors. [<xref ref-type="bibr" rid="B1">1</xref>]</p><p>The impact of viral load on antiviral T-cell responses has been precisely characterized in animal models of viral infections: a sustained presence of viral antigens leads to virus specific T cell deletion [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>In HBV infection the frequency and function of circulatory and intrahepatic HBV specific CD8 T cells is inversely proportional to the level of HBV-DNA. [<xref ref-type="bibr" rid="B3">3</xref>]</p><p>The immunological defects could be proportional to the level of HBV infection and inhibition of viral replication and through antiviral treatment it is possible to obtaine a partial restoration of HBV specific T cell immunity [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>] which is inadeguate in elderly patients. [<xref ref-type="bibr" rid="B6">6</xref>]</p><p>Moreover recent studies have provided evidence that a population of specialized T cells are able to regulate the immune response.</p><p>These cells reside mainly within a minor population of CD4 cells that express the phenotype marker CD 25. [<xref ref-type="bibr" rid="B7">7</xref>]</p><p>They have been shown to suppress immunological responses against self and foreign antigens through suppressive cytokines.</p><p>It is possible that CD4+ CD25+ T cells are responsible for the weak HBV specific T cell response in HBV infection and may inhibit the expansion and function of HBV specific CD8 T cells precluding HBV clearance.</p><p>Some authors showed that the frequency of CD4+ CD25+ T cells positively correlate with HBVDNA load. [<xref ref-type="bibr" rid="B6">6</xref>]</p><p>This result suggests that an increased level of T regs may be associated with a negative immune response, leading to poor viral clearance.</p><p>Our hypothesis is that a decrease of HBV DNA load, determined by lamivudine treatment, determines a downregulation of T regs.</p><p>T regs could be able suppressing the population and gamma IFN production, mediated by HbsAg.</p><p>In summary, our findings suggest that it could be possible a marked increase in circulating Tregs in elderly patients with HBV infection.</p><p>Taken together these data, it is possible that antiviral drugs might be useful in a selected group of old patients in which HBV may cause a severe form of acute hepatitis, caused by a decline of immunity and by the frequent presence of other morbidities.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>GM performed the study and wrote the article.</p><p>AP and OP designed the study and reviewed the article.</p><p>CS, PB and VR analized the clinical data for the study.</p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lok</surname><given-names>AS</given-names></name><name><surname>McMahon</surname><given-names>BJ</given-names></name></person-group><article-title>Chronic hepatitis B</article-title><source>Hepatology</source><year>2001</year><volume>34</volume><fpage>1225</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">11732013</pub-id><pub-id pub-id-type="doi">10.1053/jhep.2001.29401</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maini</surname><given-names>HK</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Oggs</surname><given-names>GS</given-names></name></person-group><article-title>Direct ex vivo analysis of hepatitis B virus specific CD8+ T cells....with the control of infection</article-title><source>Gastroenterology</source><year>1999</year><volume>117</volume><fpage>1386</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">10579980</pub-id><pub-id pub-id-type="doi">10.1016/S0016-5085(99)70289-1</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dusheinko</surname><given-names>G</given-names></name></person-group><article-title>Hepatitis B</article-title><source>J Hepatology</source><year>2003</year><volume>44</volume><fpage>948</fpage><lpage>89</lpage></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Penna</surname><given-names>A</given-names></name><name><surname>Bertoletti</surname><given-names>A</given-names></name><name><surname>Lamonaca</surname><given-names>V</given-names></name><name><surname>Rapti</surname><given-names>I</given-names></name><name><surname>Cavalli</surname><given-names>A</given-names></name><name><surname>Cerioni</surname><given-names>S</given-names></name><name><surname>Panebianco</surname><given-names>R</given-names></name><name><surname>Jenkins</surname><given-names>J</given-names></name><name><surname>Ferrari</surname><given-names>C</given-names></name></person-group><article-title>Transient restoration R, of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B</article-title><source>J Hepatol</source><year>2003</year><volume>39</volume><fpage>595</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">12971971</pub-id><pub-id pub-id-type="doi">10.1016/S0168-8278(03)00292-7</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rigopoulou</surname><given-names>EI</given-names></name><name><surname>Suri</surname><given-names>D</given-names></name><name><surname>Chokshi</surname><given-names>S</given-names></name><name><surname>Mullerova</surname><given-names>I</given-names></name><name><surname>Rice</surname><given-names>S</given-names></name><name><surname>Tedder</surname><given-names>RS</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name><name><surname>Naoumov</surname><given-names>NV</given-names></name></person-group><article-title>Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity</article-title><source>Hepatology</source><year>2005</year><volume>42</volume><fpage>1028</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">16250037</pub-id><pub-id pub-id-type="doi">10.1002/hep.20888</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suvas</surname><given-names>S</given-names></name><name><surname>Kumaraguru</surname><given-names>U</given-names></name><name><surname>Pack</surname><given-names>CD</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Rouse</surname><given-names>BT</given-names></name></person-group><article-title>CD4+CD25+ T cells regulate virus- specific primary and memory CD8+ T cell responses</article-title><source>J Exp Med</source><year>2003</year><volume>198</volume><fpage>889</fpage><lpage>901</lpage><pub-id pub-id-type="pmid">12975455</pub-id><pub-id pub-id-type="doi">10.1084/jem.20030171</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guidotti</surname><given-names>LG</given-names></name><name><surname>Chisari</surname><given-names>PV</given-names></name></person-group><article-title>Noncytolytic control of viral infections by the innate and adaptive immune response</article-title><source>Annu Rev immunol</source><year>2001</year><volume>19</volume><fpage>65</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">11244031</pub-id><pub-id pub-id-type="doi">10.1146/annurev.immunol.19.1.65</pub-id></citation></ref></ref-list></back></article>